Imperial College Faculty of Medicine

Chula Launches the Latest Parkinson's Gloves to Reduce Tremors

Retrieved on: 
Thursday, November 2, 2023
Tremor, Improvement Science Research Network, Ageing, Faculty, PD, Patent, Innovation, Public, Government, Parkinson's disease, Family, King Chulalongkorn Memorial Hospital, Psychedelic treatments for trauma-related disorders, Private, Disease, Organization, Ministry, Private sector, Quality of life, Ministry of Higher Education (Syria), Sulfotransferase, Injury, Risk, Speed, Imperial College Faculty of Medicine, Hand, Patient, Motion, Chulalongkorn University, Memory, Pharmaceutical industry, Medical device, Health insurance, Personal protective equipment, Research, Science, Environment, Medicine

The current method of treating Parkinson's is taking a cocktail of medications, which is mostly unable to reduce all the tremors.

Key Points: 
  • The current method of treating Parkinson's is taking a cocktail of medications, which is mostly unable to reduce all the tremors.
  • "The tremor-reducing Parkinson's gloves are the first medical device that can help reduce tremors in the hands of PD patients through automatic electric stimulation of the hand muscles.
  • We hope this will help reduce the tremors for the patients without having to increase the dosage of their medication unnecessarily and reduce the risk of brain surgery," discussed Asst.
  • The gloves can be used to reduce tremors in the hand from other conditions as well.

Chula Launches the Latest Parkinson's Gloves to Reduce Tremors

Retrieved on: 
Thursday, November 2, 2023
Tremor, Improvement Science Research Network, Ageing, Faculty, PD, Patent, Innovation, Public, Government, Parkinson's disease, Family, King Chulalongkorn Memorial Hospital, Psychedelic treatments for trauma-related disorders, Private, Disease, Organization, Ministry, Private sector, Quality of life, Ministry of Higher Education (Syria), Sulfotransferase, Injury, Risk, Speed, Imperial College Faculty of Medicine, Hand, Patient, Motion, Chulalongkorn University, Memory, Pharmaceutical industry, Medical device, Health insurance, Personal protective equipment, Research, Science, Environment, Medicine

The current method of treating Parkinson's is taking a cocktail of medications, which is mostly unable to reduce all the tremors.

Key Points: 
  • The current method of treating Parkinson's is taking a cocktail of medications, which is mostly unable to reduce all the tremors.
  • "The tremor-reducing Parkinson's gloves are the first medical device that can help reduce tremors in the hands of PD patients through automatic electric stimulation of the hand muscles.
  • We hope this will help reduce the tremors for the patients without having to increase the dosage of their medication unnecessarily and reduce the risk of brain surgery," discussed Asst.
  • The gloves can be used to reduce tremors in the hand from other conditions as well.

NHS Study Demonstrates Eko Smart Stethoscope Can Identify Heart Failure

Retrieved on: 
Tuesday, February 1, 2022
Diagnosis, Imperial College London, Patient, Artificial intelligence, Eko, AI, Mayo Clinic, Stroke, Imperial College Faculty of Medicine, Echocardiography, NHS, American Heart Association, Sutter Health, DUO, Clinical professor, Heart failure, Cardiovascular disease, Lancet, Heart, Highland Capital Partners, FDA, Stethoscope, National Heart, Lung, and Blood Institute, Medical device, Cardiology

"The result will be earlier diagnosis and treatment and the avoidance of unnecessary and expensive tests for those in whom heart failure is ruled out.

Key Points: 
  • "The result will be earlier diagnosis and treatment and the avoidance of unnecessary and expensive tests for those in whom heart failure is ruled out.
  • Using the Eko DUO ECG + Digital Stethoscope with ELEFT, heart failure caused by a weakened heart pump can be detected in seconds during a stethoscope exam.
  • Point-of-care screening for heart failure with reduced ejection fraction using artificial intelligence during ECG-enabled stethoscope examination in London, UK: a prospective, observational, multicentre study.
  • Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022
Amlodipine, III, Indapamide, Patient, Research, Imperial College Healthcare NHS Trust, Academic clinical trial, George Institute for Global Health, Clinical trial, Pharmacology, International Society, Infarction, COVID-19, Guideline, Vascular dementia, Medical school, Safety, Death, Faculty, CEO, Stroke, World, School, NHS, Public health, Industry, Blood pressure, Imperial College Faculty of Medicine, Loma Linda University School of Public Health, Department of Nutrition, Cardiovascular disease, Type 2 diabetes, Heart, WHO, Medicine, Telmisartan, GP, International Society on Hypertension in Blacks, World Health Organization, Global Health, ICTU, Imperial College London, Hospital, Degenerative disease, Pharmaceutical industry, Hypertension

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022
Amlodipine, III, Indapamide, Patient, Research, Imperial College Healthcare NHS Trust, Academic clinical trial, George Institute for Global Health, Clinical trial, Pharmacology, International Society, Infarction, COVID-19, Guideline, Vascular dementia, Medical school, Safety, Death, Faculty, CEO, Stroke, World, School, NHS, Public health, Industry, Blood pressure, Imperial College Faculty of Medicine, Loma Linda University School of Public Health, Department of Nutrition, Cardiovascular disease, Type 2 diabetes, Heart, WHO, Medicine, Telmisartan, GP, International Society on Hypertension in Blacks, World Health Organization, Global Health, ICTU, Imperial College London, Hospital, Degenerative disease, Pharmaceutical industry, Hypertension

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

Riverside University Health System Medical Center, Skymount Medical Begin U.S. Clinical Trial for COVID-19 Oral Therapeutics Discovered Using Artificial Intelligence

Retrieved on: 
Wednesday, November 3, 2021
Safety, Riverside University Health System Medical Center, Trauma Center, Research, University, Louisiana, Mental health, Global health, LSU Department of Finance, Louisiana State University, Human, Illinois Institute of Technology, Community, Imperial College Faculty of Medicine, Faculty, Patient, FDA, Drug discovery, LSU, Infection, Severe acute respiratory syndrome coronavirus 2, Time, Institutional review board, Silver, Medicine, Intelligence, Adult, Public health, Clinical trial, Medical school, COVID-19, Multimedia, Comparative effectiveness research, Computer science, Medical Center, Drug design, Artificial intelligence, AB, Health, BATON, RUHS, Hospital, Therapy, IRB, Particle-size distribution, Chief scientific officer, Bed, AI, Pharmaceutical industry, Medical device

CALGARY, AB andMORENO VALLEY, Calif. and BATON ROUGE, La., Nov. 3, 2021 /PRNewswire/ --Skymount Medical has partnered with Riverside University Health System (RUHS) Medical Center to conduct the first U.S. clinical trial on the efficacy of COVID-19 oral therapeutics discovered by LSU researchers using artificial intelligence (AI).

Key Points: 
  • CALGARY, AB andMORENO VALLEY, Calif. and BATON ROUGE, La., Nov. 3, 2021 /PRNewswire/ --Skymount Medical has partnered with Riverside University Health System (RUHS) Medical Center to conduct the first U.S. clinical trial on the efficacy of COVID-19 oral therapeutics discovered by LSU researchers using artificial intelligence (AI).
  • The testing will be conducted through RUHS Medical Center's Comparative Effectiveness & Clinical Outcomes Research Center (CECORC) in Moreno Valley.
  • The study will be a double-blind intervention conducted in an outpatient setting, comparing the two-drug combination to a placebo.
  • Skymount Medical's mission is to accelerate the development of better medicines using DeepDrug, drug design software leveraged by artificial intelligence developed by researchers at Louisiana State University (LSU).

First-of-its-Kind, Global Data Repository for Interstitial Lung Diseases Launches Through Academic and Industry Collaborative

Retrieved on: 
Tuesday, September 7, 2021

HOLLAND, Mich., Sept. 7, 2021 /PRNewswire/ -- The Open Source Imaging Consortium (OSIC) today announced the launch of its global, data-rich repository of anonymized HRCT scans and clinical information regarding interstitial lung diseases (ILDs). This first-of-its-kind database is the world's largest and most diverse, with a plethora of real world clinical and imaging data that is both multi-ethnic and multi-center. The OSIC Data Repository currently houses close to 1,500 anonymized and quality-controlled scans with accompanying data, and has an additional 5,000 in the quality control queue. It is on track to reach its goal of 15,000 anonymized scans, available to OSIC members, by first quarter 2022.

Key Points: 
  • The OSIC Data Repository currently houses close to 1,500 anonymized and quality-controlled scans with accompanying data, and has an additional 5,000 in the quality control queue.
  • It is on track to reach its goal of 15,000 anonymized scans, available to OSIC members, by first quarter 2022.
  • The OSIC Data Repository was built with images and clinical data from a variety of sources, and every scan has been anonymized with a personal and automated quality control check.
  • "Data is the essence of scientific progress and the OSIC Data Repository already contains preliminary data rich enough to better understand the causes of disease, leading to better treatment and patient outcomes."

First-of-its-Kind, Global Data Repository for Interstitial Lung Diseases Launches Through Academic and Industry Collaborative

Retrieved on: 
Tuesday, September 7, 2021

HOLLAND, Mich., Sept. 7, 2021 /PRNewswire/ -- The Open Source Imaging Consortium (OSIC) today announced the launch of its global, data-rich repository of anonymized HRCT scans and clinical information regarding interstitial lung diseases (ILDs). This first-of-its-kind database is the world's largest and most diverse, with a plethora of real world clinical and imaging data that is both multi-ethnic and multi-center. The OSIC Data Repository currently houses close to 1,500 anonymized and quality-controlled scans with accompanying data, and has an additional 5,000 in the quality control queue. It is on track to reach its goal of 15,000 anonymized scans, available to OSIC members, by first quarter 2022.

Key Points: 
  • The OSIC Data Repository currently houses close to 1,500 anonymized and quality-controlled scans with accompanying data, and has an additional 5,000 in the quality control queue.
  • It is on track to reach its goal of 15,000 anonymized scans, available to OSIC members, by first quarter 2022.
  • "We've seen efforts like this in common diseases, but nothing truly like it for rare diseases.
  • "Data is the essence of scientific progress and the OSIC Data Repository already contains preliminary data rich enough to better understand the causes of disease, leading to better treatment and patient outcomes."